The present invention relates to rusalatide acetate compositions, formulations and dosage forms that include 23 amino acid monomer (“Monomer”), dimer (“Dimer”) of two 23 amino acid Monomers, or any combination of Monomer and Dimer, wherein any ratio, proportion or percentage of Monomer and Dimer may be present in the compositions, formulations and dosage forms. The invention also broadly covers stable compositions, formulations or dosage forms that include rusalatide acetate and any pharmaceutically acceptable salts thereof.